The FDA's outside experts on Wednesday weighed in on the potential risks of dermal fillers for the décolletage area, particularly in regards to possible interference with breast cancer screening and imaging, and how these risks could be mitigated.

While the dermal filler Radiesse received European approval to fill wrinkles and provide volume in the décolletage area -- broadly defined as the upper chest up to the neck -- the FDA is concerned about a number of risks with these products, especially the possibility that filler materials could interfere with breast cancer screening and imaging. No product is currently approved in the U.S. for such use.

In a briefing document ahead of Wednesday's meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Com

See Full Page